Nanomedicine

1 Nanomedicine: working towards defining the field.- 2 Complement regulators and inhibitors in health and disease: A structural perspective.- 3 The art of complement: complement sensing of nanoparticles and consequences.- 4 The nanoscience of polyvalent binding by proteins in the immune response .- 5 Microfluidics-based Single Cell Analytical Platforms for Characterization of Cancer.- 6 Nanotheranostics and in-vivo imaging.- 7 Targeting cancer using nanocarriers.- 8 The importance of particle geometry in design of therapeutic and imaging nanovectors.- 9 Delivery of peptides and proteins to the brain using nano-drug delivery systems and other formulations.- 10 Polymer-based DNA delivery systems for cancer immunotherapy.- 11 The use of silk in nanomedicine applications.- 12 Nanotoxicology and regulatory affairs.- 13 The application of nanotechnology for implant drug release.- 14 Guided cellular responses by surface cues for nanomedicine applications 

Kenneth Alan Howard is an Associate Professor and Group Leader at the Department of Molecular Biology at the Interdisciplinary Nanoscience Center (iNANO), Aarhus University, Denmark. His research and teaching activities are focused on delivery science, nanomedicine and RNA interference. Kenneth Alan Howard received a PhD in Pharmaceutical Science from the University of Nottingham, UK, and has held postdoctoral positions at the CRC Institute for Cancer Studies, University of Birmingham, UK and the School of Pharmacy, University of London. Dr Howard is an active member of the Controlled Release Society serving on the Board of Scientific Advisors (chair), Nominations Committee and organizer of a CRS Educational workshops "RNA Interference Biology and Therapeutics" and "Albumin: the next generation therapeutic. Dan Peer is a translational scientist and Professor that leads an NIH-funded lab in the Faculty of Life Science and the Faculty of Engineering at Tel Aviv University (TAU). He is also the Director of the Focal Technology Area (FTA) on Nanomedicines for Personalized Theranostics, a National Nanotechnology Initiative and the Director of the Leona M. and Harry B. Helmsley Nanotechnology Research Fund. Prof. Peer's work was among the first to demonstrate systemic delivery of RNAi molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference (RNAi) for in vivo validation of new drug targets within the immune system. He is an editor of several books in the field of nanomedicine, Editor of Molecular and Cellular Therapies (Springer); Editor of Biology and Medicine in Nanotechnology (IOP), an Associate Editor of the Journal of Controlled Release (Elsevier); Journal of Biomedical Nanotechnology, and of Biochemistry, and on the Editorial Boards of the Biomedical Microdevices (Springer), Cancer Letters (Elsevier), Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and Bioconjugate Chemistry (ACS). Prof. Peer is currently

"This engrossing book is devoted to nanomedicine, one of the fastest-growing and revolutionary branches of healthcare. ... The book Nanomedicine provides a well-done and up-to-date review of hot topics in the field of nanomedicine and gives insight to this exciting interdisciplinary subject." (Alena Gabelova, Neoplasma, Vol. 64 (2), 2017)